{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T14:37:24Z","timestamp":1785854244258,"version":"3.56.0"},"reference-count":45,"publisher":"BMJ","issue":"1","license":[{"start":{"date-parts":[[2024,1,5]],"date-time":"2024-01-05T00:00:00Z","timestamp":1704412800000},"content-version":"unspecified","delay-in-days":4,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Case Rep"],"accepted":{"date-parts":[[2023,12,23]]},"published-print":{"date-parts":[[2024,1]]},"abstract":"<jats:p>Thrombotic microangiopathy (TMA) is a rare but serious side effect of tyrosine kinase inhibitor (TKI) therapy. Previous case reports of renal TMA have usually occurred in the first few months of TKI initiation with only very few cases occurring within 2\u20133 years. We report a case of a patient who was referred to the Nephrology service for nephrotic syndrome and worsening renal function after 8 years of sunitinib therapy for metastatic clear cell carcinoma of the kidney. Renal biopsy showed chronic TMA without another secondary aetiology identified. With discontinuation of sunitinib and pharmacological optimisation of his hypertension, his renal function and proteinuria both significantly improved. No relapse or recurrence of disease activity was noted after a year of follow-up. This case highlights the importance of remaining vigilant for the development of renal TMA even after an extended duration of TKI therapy.<\/jats:p>","DOI":"10.1136\/bcr-2023-255841","type":"journal-article","created":{"date-parts":[[2024,1,10]],"date-time":"2024-01-10T00:43:08Z","timestamp":1704847388000},"page":"e255841","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":5,"title":["Chronic thrombotic microangiopathy presenting as acute nephrotic syndrome in a patient with renal cancer receiving tyrosine kinase inhibitor therapy"],"prefix":"10.1136","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9165-4920","authenticated-orcid":false,"given":"Anukul","family":"Ghimire","sequence":"first","affiliation":[{"name":"Medicine, University of Calgary, Calgary, Alberta, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca","family":"Brassington","sequence":"additional","affiliation":[{"name":"Pathology, Faculty of Medicine & Dentistry, University of Alberta, Edmonton, Alberta, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kim","family":"Solez","sequence":"additional","affiliation":[{"name":"Pathology, Faculty of Medicine & Dentistry, University of Alberta, Edmonton, Alberta, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aminu","family":"Bello","sequence":"additional","affiliation":[{"name":"Nephrology and Immunology, Faculty of Medicine & Dentistry, University of Alberta, Edmonton, Alberta, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2024,1,5]]},"reference":[{"key":"2025082702023277000_17.1.e255841.1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbrc.2007.02.156"},{"key":"2025082702023277000_17.1.e255841.2","doi-asserted-by":"publisher","DOI":"10.1159\/000241551"},{"key":"2025082702023277000_17.1.e255841.3","doi-asserted-by":"crossref","first-page":"ix83","DOI":"10.1093\/annonc\/mdm298","article-title":"New challenges in kidney cancer therapy: Sunitinib","volume":"18 Suppl 9","author":"Izzedine","year":"2007","journal-title":"Ann Oncol"},{"key":"2025082702023277000_17.1.e255841.4","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa065044"},{"key":"2025082702023277000_17.1.e255841.5","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfn687"},{"key":"2025082702023277000_17.1.e255841.6","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2022.1088031","article-title":"Drug-induced thrombotic microangiopathy: an updated review of causative drugs, pathophysiology, and management","volume":"13","author":"Mazzierli","year":"2022","journal-title":"Front Pharmacol"},{"key":"2025082702023277000_17.1.e255841.7","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfn657"},{"key":"2025082702023277000_17.1.e255841.8","doi-asserted-by":"crossref","first-page":"6","DOI":"10.4103\/0973-1482.172575","article-title":"Sunitinib-induced thrombotic microangiopathy","volume":"12","author":"Noronha","year":"2016","journal-title":"J Cancer Res Ther"},{"key":"2025082702023277000_17.1.e255841.9","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdm454"},{"key":"2025082702023277000_17.1.e255841.10","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfp666"},{"key":"2025082702023277000_17.1.e255841.11","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(07)70037-2"},{"key":"2025082702023277000_17.1.e255841.12","doi-asserted-by":"publisher","DOI":"10.4143\/crt.2008.40.4.211"},{"key":"2025082702023277000_17.1.e255841.13","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djm311"},{"key":"2025082702023277000_17.1.e255841.14","doi-asserted-by":"publisher","DOI":"10.1159\/000319885"},{"key":"2025082702023277000_17.1.e255841.15","doi-asserted-by":"publisher","DOI":"10.1093\/ndtplus\/sfn013"},{"key":"2025082702023277000_17.1.e255841.16","doi-asserted-by":"publisher","DOI":"10.1097\/MJT.0b013e3181eefe8b"},{"key":"2025082702023277000_17.1.e255841.17","doi-asserted-by":"publisher","DOI":"10.1053\/j.ajkd.2010.11.030"},{"key":"2025082702023277000_17.1.e255841.18","doi-asserted-by":"crossref","first-page":"163","DOI":"10.4274\/tjh.galenos.2020.2020.0532","article-title":"An interesting case: Sunitinib-induced microangiopathic hemolytic anemia and nephrotic syndrome","volume":"38","author":"Haks\u00f6yler","year":"2021","journal-title":"Turk J Haematol"},{"key":"2025082702023277000_17.1.e255841.19","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1038\/s41379-018-0186-4","article-title":"Bevacizumab-associated glomerular microangiopathy","volume":"32","author":"Person","year":"2019","journal-title":"Mod Pathol"},{"key":"2025082702023277000_17.1.e255841.20","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1007\/s10157-018-1596-9","article-title":"Bevacizumab-induced thrombotic microangiopathy and nephrotic syndrome","volume":"23","author":"Shimamura","year":"2019","journal-title":"Clin Exp Nephrol"},{"key":"2025082702023277000_17.1.e255841.21","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.21037\/tau.2020.03.41","article-title":"Renal cell carcinoma with nephrotic syndrome: a case report and literature review","volume":"9","author":"Song","year":"2020","journal-title":"Transl Androl Urol"},{"key":"2025082702023277000_17.1.e255841.22","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000000207","article-title":"Kidney diseases associated with anti-vascular endothelial growth factor (VEGF): an 8-year observational study at a single center","volume":"93","author":"Izzedine","year":"2014","journal-title":"Medicine (Baltimore)"},{"key":"2025082702023277000_17.1.e255841.23","doi-asserted-by":"publisher","DOI":"10.4103\/0971-4065.107215"},{"issue":"may28 1","key":"2025082702023277000_17.1.e255841.24","doi-asserted-by":"crossref","DOI":"10.1136\/bcr-2013-201183","article-title":"Uncommon side effect with a commonly used targeted agent: Sunitinib-induced nephrotic syndrome in a patient with metastatic renal cell carcinoma","volume":"2014","author":"Quintyne","year":"2014","journal-title":"BMJ Case Rep"},{"key":"2025082702023277000_17.1.e255841.25","doi-asserted-by":"publisher","DOI":"10.1007\/s00467-013-2696-0"},{"key":"2025082702023277000_17.1.e255841.26","doi-asserted-by":"crossref","DOI":"10.1186\/s12882-022-02789-5","article-title":"Sunitinib-related high-grade proteinuria and allograft dysfunction in a kidney recipient: a rare case report","volume":"23","author":"Ko","year":"2022","journal-title":"BMC Nephrol"},{"key":"2025082702023277000_17.1.e255841.27","doi-asserted-by":"crossref","DOI":"10.1136\/bcr-2021-243567","article-title":"Worsening membranous nephropathy in a patient with GIST treated with Sunitinib","volume":"14","author":"Zonoozi","year":"2021","journal-title":"BMJ Case Rep"},{"key":"2025082702023277000_17.1.e255841.28","doi-asserted-by":"crossref","DOI":"10.1186\/s12882-018-1181-1","article-title":"Successful re-administration of Pazopanib in a patient with metastatic renal cell carcinoma and a history of Pazopanib-induced nephrotic syndrome: a case report","volume":"20","author":"Jeon","year":"2019","journal-title":"BMC Nephrol"},{"key":"2025082702023277000_17.1.e255841.29","doi-asserted-by":"publisher","DOI":"10.3904\/kjim.2014.29.1.40"},{"key":"2025082702023277000_17.1.e255841.30","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0707330"},{"key":"2025082702023277000_17.1.e255841.31","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfl565"},{"key":"2025082702023277000_17.1.e255841.32","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gft465"},{"key":"2025082702023277000_17.1.e255841.33","doi-asserted-by":"crossref","first-page":"975","DOI":"10.4161\/cbt.29187","article-title":"Dual VEGF\/VEGFR inhibition in advanced solid malignancies: clinical effects and pharmacodynamic biomarkers","volume":"15","author":"Mittal","year":"2014","journal-title":"Cancer Biol Ther"},{"key":"2025082702023277000_17.1.e255841.34","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1016\/j.nefro.2021.08.004","article-title":"S\u00edndrome Nefr\u00f3tico Como Manifestaci\u00f3n de Microangiopat\u00eda Tromb\u00f3tica Secundaria al USO Cr\u00f3nico de Sunitinib","volume":"42","author":"Nieto-R\u00edos","year":"2022","journal-title":"Nefrolog\u00eda"},{"key":"2025082702023277000_17.1.e255841.35","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1159\/000345946","article-title":"Development of a nephrotic syndrome in a patient with gastrointestinal Stromal tumor during a long-time treatment with Sunitinib","volume":"5","author":"Pallotti","year":"2012","journal-title":"Case Rep Oncol"},{"key":"2025082702023277000_17.1.e255841.36","doi-asserted-by":"crossref","unstructured":"Fogo AB , Cohen AH , Colvin RB , et al . Fundamentals of renal pathology. Berlin, Heidelberg, 2014. doi:10.1007\/978-3-642-39080-7","DOI":"10.1007\/978-3-642-39080-7"},{"key":"2025082702023277000_17.1.e255841.37","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1007\/s00441-016-2377-y","article-title":"Expression of vascular endothelial growth factor (VEGF)-B and its receptor (Vegfr1) in murine heart, lung and kidney","volume":"365","author":"Muhl","year":"2016","journal-title":"Cell Tissue Res"},{"key":"2025082702023277000_17.1.e255841.38","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2014010060"},{"key":"2025082702023277000_17.1.e255841.39","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2018080853"},{"key":"2025082702023277000_17.1.e255841.40","doi-asserted-by":"publisher","DOI":"10.2174\/157016110790226606"},{"key":"2025082702023277000_17.1.e255841.41","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfm774"},{"key":"2025082702023277000_17.1.e255841.42","doi-asserted-by":"publisher","DOI":"10.1046\/j.1523-1755.2003.00097.x"},{"key":"2025082702023277000_17.1.e255841.43","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2015091048"},{"key":"2025082702023277000_17.1.e255841.44","doi-asserted-by":"publisher","DOI":"10.1161\/HYPERTENSIONAHA.115.05435"},{"key":"2025082702023277000_17.1.e255841.45","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2021060794"}],"container-title":["BMJ Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bcr-2023-255841","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,27]],"date-time":"2025-08-27T09:02:42Z","timestamp":1756285362000},"score":1,"resource":{"primary":{"URL":"https:\/\/casereports.bmj.com\/lookup\/doi\/10.1136\/bcr-2023-255841"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1]]},"references-count":45,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,1,5]]},"published-print":{"date-parts":[[2024,1]]}},"alternative-id":["10.1136\/bcr-2023-255841"],"URL":"https:\/\/doi.org\/10.1136\/bcr-2023-255841","relation":{},"ISSN":["1757-790X"],"issn-type":[{"value":"1757-790X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1]]}}}